Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO)

Historical Holders from Q4 2017 to Q3 2025

Symbol
SPRO on Nasdaq
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
55,705,828
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
11,311,502
Holdings value
$21,264,964
% of all portfolios
0%
Number of holders
47
Number of buys
25
Number of sells
-17
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GSK plc 16.4% $6,709,142 9,190,606 GSK PLC 27 Mar 2025
Anson Funds Management LP 2.9% $4,587,932 1,615,469 Anson Funds Management LP 30 Jun 2025

Institutional Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 11,311,502 $21,264,964 -$925,483 $1.88 47
2025 Q2 11,078,704 $32,127,617 -$7,947,299 $2.9 44
2025 Q1 15,108,016 $10,875,927 -$477,165 $0.72 38
2024 Q4 15,679,985 $16,148,583 +$400,519 $1.03 50
2024 Q3 12,343,754 $16,539,251 -$2,018,983 $1.34 46
2024 Q2 13,876,978 $18,039,320 +$23,111 $1.3 47
2024 Q1 13,757,012 $23,665,168 -$10,720 $1.72 54
2023 Q4 13,365,697 $19,647,483 +$254,060 $1.47 46
2023 Q3 14,186,051 $17,161,812 -$230,667 $1.21 53
2023 Q2 14,363,122 $20,824,354 +$224,803 $1.45 56
2023 Q1 14,249,435 $20,599,780 -$6,707 $1.45 46
2022 Q4 14,222,474 $24,601,496 -$11,539,486 $1.73 57
2022 Q3 19,852,133 $39,711,772 +$134,944 $2 61
2022 Q2 20,944,051 $15,519,733 -$13,723,970 $0.7409 60
2022 Q1 20,241,451 $176,086,818 +$3,320,960 $8.7 96
2021 Q4 19,791,141 $316,661,728 +$1,752,850 $16.01 82
2021 Q3 18,370,536 $338,246,936 +$16,477,961 $18.41 87
2021 Q2 16,107,401 $224,862,846 -$15,083,084 $13.96 82
2021 Q1 18,548,675 $273,055,350 +$11,246,827 $14.72 89
2020 Q4 19,088,635 $370,127,115 +$23,864,503 $19.39 87
2020 Q3 16,774,007 $187,077,092 +$55,385,284 $11.16 77
2020 Q2 11,755,382 $159,039,554 +$6,802,405 $13.53 76
2020 Q1 11,530,942 $93,166,538 +$5,358,513 $8.08 60
2019 Q4 10,816,370 $103,998,595 +$4,177,290 $9.61 61
2019 Q3 10,374,836 $109,974,592 -$2,905,980 $10.6 59
2019 Q2 10,642,327 $122,390,354 +$15,770,919 $11.51 60
2019 Q1 9,265,285 $118,611,567 +$3,622,037 $12.81 53
2018 Q4 9,098,891 $56,002,988 -$16,910,081 $6.15 50
2018 Q3 10,749,538 $112,996,000 +$24,528,130 $10.51 51
2018 Q2 8,120,919 $119,131,433 +$30,467 $14.67 42
2018 Q1 7,704,769 $109,789,119 -$578,036 $14.25 34
2017 Q4 7,758,590 $91,157,605 +$91,039,605 $11.75 36